01—Abstract
Summary
Summary of the 8-K filed November 6, 2025. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) filed an 8-K on November 6, 2025, to report its third-quarter financial results for the period ended September 30, 2025.
The filing primarily serves as a notification of the press release containing these results, which is furnished as Exhibit 99.1. Investors should refer to this press release for detailed financial performance, operational updates, and forward-looking statements related to the company's mRNA pipeline and commercial products. While the 8-K itself is procedural, it signals the release of crucial information regarding Moderna's revenue, earnings, cash position, and progress on key development programs.
The furnished press release is the primary source for understanding the company's performance during the third quarter and its outlook for the remainder of the fiscal year. Investors are encouraged to review Exhibit 99.1 for comprehensive insights into Moderna's business operations and financial health.
02—Key points
Key Highlights
- Moderna, Inc. (MRNA) announced its third-quarter financial results for the period ending September 30, 2025.
- The company filed an 8-K on November 6, 2025, to furnish a press release detailing these results.
- The press release, furnished as Exhibit 99.1, is the primary document for investors to review for Q3 financial performance.
- Key financial metrics, operational updates, and business outlook are expected to be disclosed in the press release.
- The filing serves as an official notification of the release of Q3 2025 earnings information.
- Investors should consult Exhibit 99.1 for specific revenue, earnings, and pipeline development details.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The main purpose of this 8-K filing is to officially notify the public and the SEC that Moderna, Inc. has released its financial results for the third quarter ended September 30, 2025. The detailed results are contained in a press release furnished as Exhibit 99.1.
Where can I find the actual financial results for the third quarter?
The actual financial results for the third quarter are located in the press release issued by Moderna, Inc. on November 6, 2025, which is attached as Exhibit 99.1 to this 8-K filing. You should refer to Exhibit 99.1 for detailed financial performance and operational updates.
Does this 8-K filing contain the specific Q3 2025 revenue and earnings figures?
This 8-K filing itself does not contain the specific financial figures. It is a notification that the results have been released in a separate press release (Exhibit 99.1). You will need to access Exhibit 99.1 to find the detailed revenue, earnings, and other financial metrics for the third quarter.
Is this information considered 'filed' with the SEC, or is it 'furnished'?
The information in this 8-K filing, including Exhibit 99.1, is intended to be furnished, not 'filed' in the traditional sense that would subject it to Section 18 of the Exchange Act. However, it is incorporated by reference into any future filings where specifically noted.
04—Continue